id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S13513 R52198 |
Fitton - Calcium blockers (Controls unexposed, disease free), 2020 | Preterm birth (birth on or before 36 weeks gestation). | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified |
4.73 [2.90;7.71] excluded (control group) |
39/167 12,622/250,693 | 12,661 | 167 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S14422 R57250 |
Fitton - Calcium blockers (Controls unexposed, sick), 2020 | Preterm birth (birth on or before 36 weeks gestation) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 3.00 [2.08;4.32] C | 39/167 736/7,971 | 775 | 167 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S13387 R52258 |
Mito - Amlodipine, 2019 | Preterm birth (<37 wks) | at least 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication | 0.56 [0.26;1.24] C | 10/48 41/129 | 51 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S13449 R51810 |
Su - Calcium blockers (Controls unexposed, disease free), 2013 | Preterm birth (< 37 completed weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication |
2.66 [1.92;3.67] C excluded (control group) |
47/303 529/8,181 | 576 | 303 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S13443 R51792 |
Su - Calcium blockers (Controls unexposed, sick), 2013 | Preterm birth (< 37 completed weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Indications Antihypertensive: Only chronic hypertension indication | 2.11 [1.43;3.10] | 47/303 84/1,006 | 131 | 303 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S13987 R54924 |
Weber-Schoendorfer - Calcium blockers, 2008 | Preterm children (<37 weeks) | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified | 4.63 [2.94;7.27] | 54/227 47/722 | 101 | 227 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S13969 R54749 |
Parazzini - Nifedipine, 1998 | Preterm delivery (< 37 weeks of gestation) | 2nd and/or 3rd trimester | randomized controlled trial | unexposed, sick | Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified | 1.26 [0.77;2.07] C | 58/129 50/127 | 108 | 129 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S13988 R54961 |
Magee - Calcium blockers, 1996 | Delivery < 37 weeks | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched | 4.01 [1.03;15.62] | 18/64 6/71 | 24 | 64 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 6 studies | 2.08 [1.23;3.53] | 1,190 | 938 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Controls unexposed, sick; 2: Controls unexposed, sick;
Asymetry test p-value = 0.5521 (by Egger's regression)
slope=1.3131 (0.7627); intercept=-1.9866 (3.0638); t=0.6484; p=0.5521
excluded 13449, 13513